Search research articles
Contact Us
Filters
Showing results (271-280 of 294) with videos related to
Page
of 30
Sort By:
Journal of Translational Medicine
|
November 7, 2024
Etrinabdione (VCE-004.8), a B55α activator, promotes angiogenesis and arteriogenesis in critical limb ischemia
Adela García-Martín, María E Prados, Isabel Lastres-Cubillo, et al.
Breast Cancer Research : BCR
|
June 5, 2026
A systemic immune signature stratifies early-stage breast cancer patients and reveals soluble IL-2RA and PD-1 as potential independent prognostic biomarkers
Yoel G Montoyo-Pujol, Pascual Martínez-Peinado, Sandra Pascual-García, et al.
Cell Death and Differentiation
|
August 7, 2021
A novel CDC25A/DYRK2 regulatory switch modulates cell cycle and survival
Maribel Lara-Chica, Alejandro Correa-Sáez, Rafael Jiménez-Izquierdo, et al.
JAMA Pediatrics
|
September 1, 2017
Comparative Effectiveness and Safety of Cognitive Behavioral Therapy and Pharmacotherapy for Childhood Anxiety Disorders: A Systematic Review and Meta-analysis
Zhen Wang, Stephen P H Whiteside, Leslie Sim, et al.
The Lancet. Oncology
|
March 5, 2018
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, et al.
Thyroid : Official Journal of the American Thyroid Association
|
February 12, 2026
Pre-Radioiodine Thyrotropin Thresholds During Withdrawal Preparation in Differentiated Thyroid Cancer after Total Thyroidectomy: A Systematic Review and Meta-Analysis
Tatiana Rojas, Paola Solis-Pazmino, Luis A Figueroa, et al.
Gynecologic Oncology
|
December 16, 2018
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients
V Rodriguez-Freixinos, L Fariñas-Madrid, M Gil-Martin, et al.
Journal of Medical Virology
|
August 6, 2025
Modeling Antibody Kinetics Post-mRNA Booster Vaccination and Protection Durations Against SARS-CoV-2 Infection
Luis J Ponce, Yuqian Wang, Ananya Singh, et al.
Gynecologic Oncology
|
November 21, 2019
Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277]
V Rodriguez-Freixinos, L Fariñas-Madrid, M Gil-Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 30, 2022
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
C E Geyer, W M Sikov, J Huober, et al.
Page
of 30
Search research articles
Search
Showing results (271-280 of 294) with videos related to
Sort By:
Page
of 30
Journal of Translational Medicine
|
November 7, 2024
Etrinabdione (VCE-004.8), a B55α activator, promotes angiogenesis and arteriogenesis in critical limb ischemia
Adela García-Martín, María E Prados, Isabel Lastres-Cubillo, et al.
Breast Cancer Research : BCR
|
June 5, 2026
A systemic immune signature stratifies early-stage breast cancer patients and reveals soluble IL-2RA and PD-1 as potential independent prognostic biomarkers
Yoel G Montoyo-Pujol, Pascual Martínez-Peinado, Sandra Pascual-García, et al.
Cell Death and Differentiation
|
August 7, 2021
A novel CDC25A/DYRK2 regulatory switch modulates cell cycle and survival
Maribel Lara-Chica, Alejandro Correa-Sáez, Rafael Jiménez-Izquierdo, et al.
JAMA Pediatrics
|
September 1, 2017
Comparative Effectiveness and Safety of Cognitive Behavioral Therapy and Pharmacotherapy for Childhood Anxiety Disorders: A Systematic Review and Meta-analysis
Zhen Wang, Stephen P H Whiteside, Leslie Sim, et al.
The Lancet. Oncology
|
March 5, 2018
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl, Joyce O'Shaughnessy, Michael Untch, et al.
Thyroid : Official Journal of the American Thyroid Association
|
February 12, 2026
Pre-Radioiodine Thyrotropin Thresholds During Withdrawal Preparation in Differentiated Thyroid Cancer after Total Thyroidectomy: A Systematic Review and Meta-Analysis
Tatiana Rojas, Paola Solis-Pazmino, Luis A Figueroa, et al.
Gynecologic Oncology
|
December 16, 2018
Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients
V Rodriguez-Freixinos, L Fariñas-Madrid, M Gil-Martin, et al.
Journal of Medical Virology
|
August 6, 2025
Modeling Antibody Kinetics Post-mRNA Booster Vaccination and Protection Durations Against SARS-CoV-2 Infection
Luis J Ponce, Yuqian Wang, Ananya Singh, et al.
Gynecologic Oncology
|
November 21, 2019
Corrigendum to 'Chemotherapy and PARP inhibitors in heavily pretreated BRCA1/2 mutation ovarian cancer (BMOC) patients' [Gynecologic Oncology 152 (2019) 270-277]
V Rodriguez-Freixinos, L Fariñas-Madrid, M Gil-Martin, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
January 30, 2022
Long-term efficacy and safety of addition of carboplatin with or without veliparib to standard neoadjuvant chemotherapy in triple-negative breast cancer: 4-year follow-up data from BrighTNess, a randomized phase III trial
C E Geyer, W M Sikov, J Huober, et al.
Page
of 30